Loading
Life sciences · Journal article
Psychiatric Services · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Involuntary civil commitment (ICC) for substance use disorders is framed as a public health response to overdoses and functional impairment, yet evidence of its effectiveness remains limited. Federal attention to this practice in July 2025 heightens the need for rigorous evaluation to inform policies and clinical care. As of December 2024, a total of 36 states and the District of Columbia authorized substance-related ICC, whereas 14 states limited commitment to other psychiatric diagnoses. State laws vary regarding eligibility, safeguards, and maximum duration, and many do not require less restrictive alternatives or specify evidence-based care. Beyond this heterogeneous legal landscape, no national estimates are available regarding how many people are subjected to ICC for substance use disorders, and outcome data remain scarce. Existing evidence provides little clarity on implementation, patient-centered outcomes, postdischarge recovery, or social and ethical consequences. ICC statutes intersect with emergency and inpatient psychiatry, and they directly affect how psychiatric services evaluate overdose or suicidality, assess less restrictive alternatives, and transition patients into evidence-based addiction care. This assessment outlines a multidisciplinary research agenda focused on epidemiology, quasi-experimental evaluation, implementation, patient-centered outcomes, cost-effectiveness, and ethics. Current evidence does not support broad use of ICC for substance use disorders, and encouraging this practice risks unintended harm.